Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

Abstract

Objective Real‐world studies assessing treatment response by psoriatic arthritis (PsA) domains are limited. This study aimed to describe the patient characteristics, frequency and combinations of disease domains, disease activity, and patient‐reported outcomes (PROs) by PsA domains in patients who initiated treatment with a tumor necrosis factor inhibitor (TNFi) or interleukin‐17 inhibitor (IL‐17i). Methods Adults with PsA who initiated treatment with a TNFi or an IL‐17i between January 2013 and January 2021 and had a 6 (±3)–month follow‐up were included. The prevalence of PsA domains, the most common domain combinations, treatment persistence, and unadjusted change in disease activity and PROs from baseline to 6 months for each PsA domain were summarized descriptively. Results Of the 1005 eligible patients, 63% were receiving TNFi and 37% were receiving IL‐17i. Forty percent of TNFi and 14% of IL‐17i initiators received these treatments as first‐line therapy. Peripheral arthritis and skin disease were the most common PsA domains identified in 86% and 82% of patients, respectively, and the triad of peripheral arthritis, skin disease, and nail psoriasis was the most common domain combination observed in 14% of patients. More than two thirds (68%) of patients remained on therapy at 6 months’ follow‐up. Improvements in disease activity and PROs were observed across all PsA domains in those receiving TNFi or IL‐17i. Conclusion This real‐world analysis highlights the heterogeneity in domain presentation; therefore, assessing all PsA domains is important for optimal disease management. Improvements in outcomes across all PsA domains demonstrate the effectiveness of TNFi and IL‐17i in diverse patient groups exhibiting different phenotypes of PsA.